Show simple item record

dc.contributor.authorOluka, M O
dc.contributor.authorMitema, E S
dc.contributor.authorKibwage, IO
dc.contributor.authorKwasa, Thomas O O
dc.contributor.authorKokwaro, G O
dc.date.accessioned2013-02-19T13:16:00Z
dc.date.issued1996
dc.identifier.citationEast African Medical Journal Vol.73 No.5en
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/10336
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/pubmed/8756037
dc.description.abstractThe relative bioavailabilities of three carbamazepine tablet formulations available in the Kenyan market (Temporal", Taver" and Carbamazepine Lincoln) compared with the innovator formulation (Tegretol") were evaluated in seven healthy African volunteers (5 males, two females; aged 22-36 years), according to a randomised fourway crossover study design, following oral administration of single 200mg doses with a three week washout period. In vitro dissolution profiles ofthe tablets were also evaluated. Relative bioavailabilities (Frel) of Temporals, TaverR and Carbamazepine Linocoln were 101.2%, 82.2% and 71.6% respectively, compared with Tegretol''. Percent drug content dissolved ill vitro after I hour were 91.3%, 75.9% and 39.3% for Temporals, Taverf and Carbamazepine Lincoln, respectively. It was concluded that Temporalf was bioequivalent to Tegretol while Taver and Carbamazepin Lincoln were bioinequivalent to TegretoI. Administration of TaverR or Carbamazeplne Lincoln might lead to poor control of epileptic seizures.en
dc.language.isoenen
dc.titleA comparative bioavailability of four carbamazepine tablet formulations available in the Kenyan marketen
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record